Related Experiment Video
Updated: Jul 28, 2026
11:26
Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles
Published on: June 8, 2012
Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles
J M Koziara1, J J Oh, W S Akers
1Department of Pharmaceutical Sciences, Center of Pharmaceutical Science and Technology, College of Pharmacy, University of Kentucky, 725 Rose Street, Lexington, KY 40536-0082, USA.
Pharmaceutical Research
|September 1, 2005
Summary
Cetyl alcohol/polysorbate nanoparticles (E78 NPs), including PEG-coated versions, show good blood compatibility. These drug carriers did not lyse red blood cells and inhibited platelet activation, though high concentrations prolonged clotting time.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Lipid-based nanoparticles (E78 NPs) are being developed for targeted drug delivery.
- Systemic administration necessitates evaluation of nanoparticle hemocompatibility.
Purpose of the Study:
- To assess the hemocompatibility of pegylated and nonpegylated E78 nanoparticles.
- Focus on hemolytic activity, platelet function, and blood coagulation.
Main Methods:
- Evaluated human red blood cell lysis via hemoglobin release.
- Assessed platelet activation and aggregation using flow cytometry and aggregometry.
- Measured whole blood clotting time in human blood.
Main Results:
- E78 NPs showed no red blood cell lysis up to 1 mg/mL.
- Neither NP formulation activated platelets; they inhibited agonist-induced platelet activation and aggregation.
- E78 NPs prolonged whole blood clotting time at concentrations ≥ 500 µg/mL.
Conclusions:
- PEG-coated and nonpegylated E78 NPs demonstrate potential blood compatibility at clinical doses.
- In vivo platelet function may be affected at approximately 1 mg/mL E78 NPs.
